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The Gram-positive opportunistic pathogen Enterococcus faecalis is frequently responsible for 23 
nosocomial infections in humans and represents one of the most common bacteria isolated from 24 
recalcitrant endodontic (root canal) infections. E. faecalis is intrinsically resistant to several 25 
antibiotics routinely used in clinical settings (such as cephalosporins and aminoglycosides) and 26 
can acquire resistance to vancomycin (vancomycin resistant enterococci, VRE). The resistance 27 
of E. faecalis to several classes of antibiotics and its capacity to form biofilms cause serious 28 
therapeutic problems. In this paper, we report the isolation of several bacteriophages that target 29 
E. faecalis strains isolated from the oral cavity of patients suffering root-canal infections. All 30 
phages isolated were Siphoviridae with similar tail lengths (200-250 nm) and icosahedral heads. 31 
The genome sequences of three isolated phages were highly conserved with the exception of 32 
predicted tail protein genes that diverge in sequence, potentially reflecting host range. The 33 
properties of the phage with the broadest host-range (SHEF2), was further characterised. We 34 
showed that this phage requires interaction with components of the major and variant region 35 
Enterococcal polysaccharide antigen (Epa) to engage in lytic infection. Finally, we explored the 36 
therapeutic potential of this phage and showed that it can eradicate E. faecalis biofilms formed 37 
in vitro on a standard polystyrene surface but also on a cross-sectional tooth-slice model of 38 
endodontic infection.  We also show that SHEF2 cleared a lethal infection of zebrafish when 39 
applied in the circulation. We therefore propose that the phage described in this study could be 40 
used to treat a broad range of antibiotic resistant E. faecalis infections. 41 
 42 
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Enterococcus faecalis is a common nosocomial pathogen that is a frequently isolated 45 
from the blood stream and wound infections (1, 2). In some cases, the clinical outcomes are 46 
poor due to the limited choices of effective antimicrobial therapy and colonisation by 47 
vancomycin-resistant enterococci (VRE). One example is E. faecalis strain V583, which was the 48 
first of the vancomycin-resistant E. faecalis clinical isolates to be sequenced (3, 4). In addition 49 
E. faecalis is commonly recovered from chronic periapical or root canal infections associated 50 
with failed endodontic therapy (5, 6).  It has been proposed that this is associated with their 51 
ability to (i) live and survive in the presence of several commonly used root canal antiseptic 52 
irrigants (e.g., calcium hydroxide) (7), (ii) tolerate prolonged periods of starvation (8), (iii) form 53 
biofilms (9) and (iv) acquire antibiotic resistance (10, 11) –together this indicates that new 54 
therapeutic approaches are necessary.  55 
 Bacteriophage therapy has recently re-emerged as an attractive alternative antimicrobial 56 
strategy to treat antibiotic resistant biofilm forming pathogens. In some infections such as those 57 
associated with burn wounds caused by Pseudomonas aeruginosa and Staphylococcus aureus, 58 
phage therapy is now considered an option for topical application (12). Furthermore, in the 59 
United States, the FDA recently approved a phage-based phase I clinical trial against P. 60 
aeruginosa. Staphylococcus and Esherichia coli in chronic venous leg ulcers, illustrating that 61 
treatment using a phage cocktail was associated with no adverse reaction (13). For example, 62 
phase II clinical trials in Europe using phage therapy against chronic otitis externa caused by P. 63 
aeruginosa infection have been conducted with successful results (14). Excitingly, phage were 64 
also used intravenously in 2019 to cure a disseminated Mycobacterium abscessus  infection in 65 
a 15-year old in the UK (15) 66 
E. faecalis lytic phages have been previously isolated using indicator strains of animal 67 
origin (16, 17), non-oral human isolates and lab strains (18-21). Here, we set out to isolate 68 
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bacteriophages targeting E. faecalis strains of oral origin, isolated either directly from 69 
endodontic infections or from mouthwashes of patients receiving endodontic treatment, and 70 
from oral lesions sourced from a range of oral microbiology laboratories around Europe. A range 71 
of tailed phages were isolated from a wastewater treatment plant and characterized. We report 72 
their therapeutic potential against E. faecalis strains forming biofilms and their capacity to 73 
eradicate systemic infection in a zebrafish model of infection. Overall our data further highlight 74 
that phages have great potential as therapeutic adjuncts in oral and other infections. 75 
 76 
Materials and methods 77 
Bacterial Strains used for bacteriophage screening. Bacterial strains used in these 78 
investigations and their sources are listed in Table 1 (22). Enterococcus strains were grown 79 
aerobically with 5% CO2 at 37°C on brain heart infusion (BHI) agar (OXOID, UK). 80 
Bacteriophage isolation. Bacteriophages were isolated from wastewater collected from the 81 
inlet of a water treatment plant in the Sheffield area (UK) that treats both industrial and domestic 82 
wastewater. The water was filtered through 3M filter paper on-site to remove particles but was 83 
not treated chemically or biologically. Samples were immediately brought to the laboratory and 84 
centrifuged 7,000 x g for 15 min to remove remaining debris. The resulting supernatant was 85 
then passed through a 0.45 µm filter (Sartorius, Germany) before 200 ml of sample were further 86 
centrifuged at 35,000 x g for 90 min to pellet any phage particles. The pellets were carefully 87 
resuspended overnight in 2 ml of SM buffer (1 M Tris-HCl Buffer pH 7.4 with 5 M NaCl, 1 M 88 
MgSO4 and 1% Gelatin) at 4°C. 10 µl of the suspended sample was spotted on to a double 89 
layer agar plate. The bottom agar was composed of BHI solid agar supplemented with 5% (v/v) 90 
horse serum (OXOID, UK) and was overlaid with 3-4 ml of molten BHI soft agar (0.7%) 91 
containing 200 µl of test bacterial strain (overnight culture inoculum, OD600 撮 2). Any formed 92 
plaques were picked using a sterile Pasteur pipette, deposited in 1 ml SM buffer and incubated 93 
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overnight at 4°C before filtering through a 0.45 µm syringe filter.  Isolated phage were then 94 
expanded by infection using 100 µl of this with 200 µl of exponential growth phase indicator 95 
bacteria for 10 minutes before mixing with 2-3 ml soft agar overlay (SAO) and overnight 96 
incubation at 37°C. All phage were purified using three consecutive rounds from single-plaques. 97 
The plaques from the third round were then re-suspended in SM buffer containing 0.1% (v/v) 98 
chloroform and stored at 4°C.  99 
Phage stock preparations. In order to prepare a working phage stock with known plaque 100 
forming unit numbers (PFU), 40 ml exponential growth indicator bacteria was infected with 100 101 
µl of stored phage suspension, incubated for three hours at 37°C to allow phage to multiply and 102 
increase in number. The broth was then centrifuged at 7,000 xg for 15 min and passed through 103 
a 0.45 µm filter. Serial dilutions from the resultant broth was used in triplicate for plating in over-104 
layer SAO as previously described and PFU/ml for each isolated phage calculated.  105 
Transmission electron microscopy. Purified phage particles in SM buffer were placed onto 106 
carbon-coated copper grids and negatively stained with 2% (wt/vol) uranyl acetate for 1 min. 107 
Particles were visualised using a FEI Tecnai G2 Spirit Transmission Electron Microscope at an 108 
accelerating voltage of 80kV at the Electron Microscopy Unit in Sheffield. Electron micrographs 109 
were recorded using a Gatan Orius 1000 digital camera and Digital Micrograph software. To 110 
observe the phage along with bacteria, 1 ml exponentially growing cells were infected with 111 
phage at multiplicity of infection (MOI) of 1 for 30 min, after centrifugation at 7000 xg for 10 min, 112 
the pellet was re-suspended with 1 ml 3% glutaraldehyde for one hour (room temperature) and 113 
examined by TEM as described above. 114 
Bacteriophage concentration by precipitation with Polyethylene Glycol (PEG 8000). 115 
Further concentrations of phage was made in order to yield a suitable working suspension for 116 
protein profiling, genomic digestion, and DNA extraction. This was performed by precipitation 117 
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with PEG 8000 (23). Briefly, 200 ml of exponential phase indicator bacteria were infected with 118 
phage stock at MOI 0.01 for three hours before 1 M NaCl was added during continuous mixing 119 
at 4°C for one hour before any unlysed bacteria and cell debris were removed by centrifugation 120 
(5000 xg). To precipitate phage particles, 10% PEG 8000 w/v was gradually added with 121 
continuous mixing and left overnight at 4°C before centrifugation at 11,000 xg for 20 min to 122 
sediment precipitated phage. The resulting pellets were carefully re-suspended overnight with 1 123 
ml of SM buffer and stored at 4°C.  124 
Heat-inactivation of phage.  A phage suspension at 1x1011 PFU/ml was treated for 45 mins at 125 
80°C- which we established inactivated the virus with a 7-log -fold drop in PFU/ml. 126 
One-step growth. We used the procedure described by (24) with some modifications. Briefly, 5 127 
ml of exponentially growing cultures of E. faecalis OS16 were infected with  SHEF2 phage at 128 
MOI of 0.1. After 5 min of phage adsorption, bacteria were diluted 200 times (to prevent further 129 
infection), and incubated at 37°C. Two samples were taken every 5 min with one used to 130 
enumerate free-phages in solution; the second was treated with 1% (v/v) chloroform to release 131 
intracellular phage and was used to enumerate total phage number. Phage titers were 132 
determined as described previously and plaques counted on double layer agar plates.  133 
Analysis of phage proteins. To define the major proteins present in the bacteriophage  134 
SHEF2, 4, 5, 6, and 7, SDS-polyacrylamide gel electrophoresis (PAGE) was performed. A PEG 135 
8000 concentrated phage stock was mixed with an equal volume of chloroform in order to 136 
release the phage particles before vortexing until an emulsion formed and centrifuged at 10,000 137 
xg for 10 min. 50 µl from the upper layer (1011-1013 PFU/ml) was then mixed with 50 µl of SDS-138 
PAGE loading buffer and heated at 95°C for 7 min. 10 µl of lysate was loaded directly onto 4-139 
12% NuPAGE® Bis-Tris precast gels (Thermo fisher scientific, UK) and electrophoresed for 60 140 
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min. Gels were stained with InstantBlue (Expaedeon) and imaged using a gel documentation 141 
system (Image scanner power look1120 USG, Amersham Bioscience). 142 
Mass spectrometry 143 
In gel digestion. Gel bands were excised and diced into 1 mm pieces prior to destaining using 144 
200 mM ammonium bicarbonate (NH4HCO3), 40% v/v acetonitrile (ACN). Samples were 145 
reduced and alkylated by sequential addition of 10 mM dithiothreitol, 50 mM NH4HCO3, 50°C for 146 
30 min and 55 mM iodoacetamide, 20 min at room temperature in the dark. Gel pieces were 147 
dried using ACN, before rehydration into a 10 ng/たl solution of trypsin prepared in 50 mM 148 
NH4HCO3. Samples were digested overnight at 37°C. Peptides in the supernatant were 149 
harvested, and combined with peptides obtained by extraction of the gel pieces using 97% 150 
ACN, 0.1% (v/v) Formic acid (FA). Peptides were dried by centrifugal evaporation using a 151 
Scanvac vacuum centrifuge (Labogene, Denmark) connected to a Vacuubrand Vacuum Pump 152 
(Vacuubrand, Germany) before resuspension in 3% v/v ACN, 0.1% trifluoroacetic acid (TFA). 153 
LC-MS/MS. Peptides were analyzed by nano-HPLC (UltiMate 3000鳥HPLC System, Thermo, 154 
Hemel Hempstead, UK) coupled to an amaZon ETD MS ion trap spectrometer (Bruker 155 
Daltonics, Bremen, Germany) using nano-ESI spray. The nano-HPLC system and the ion trap 156 
spectrometer were controlled using the Bruker Compass HyStar v3.2-SR2 software. The liquid 157 
chromatography system comprised a reversed-phase precolumn (LC Packings, Dionex) for 158 
sample desalting and PepMap 100 reversed-phase C18 column, 75鳥たm x 15 cm (Thermo, 159 
Hemel Hempstead, UK), for peptide fractionation. The flow rate for precolumn loading was 30 160 
たL/min of loading buffer (97% v/v ACN, 0.1% (v/v) TFA). Peptides were analysed at a flow rate 161 
of 300鳥nL/min and separated by gradient elution using Buffer A (3% v/v ACN, 0.1% (v/v) FA) 162 
and Buffer B (97% ACN, 0.1% FA (v/v)): 4% B (0-5 min), 5-38% B (5-65 min), 38-90% B (65-68 163 
min), 90% B (68-73 min), followed by re-equilibration at 4% B.  The electrospray was operated 164 
in positive ion mode with 4500鳥V spray voltage and 10鳥 psi gas pressure, 150°C dry gas. The 165 
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end plate offset of the mass spectrometer was set to −500鳥V and for the acquisition the standard 166 
method Proteomics Auto MSMS. 167 
Database searching. Protein identifications were obtained using the Mascot software platform 168 
(MatrixScience, in house server) to perform database searching against both the EMBOSS 169 
6.5.7.0, and CDS annotation for phage  SHEF2 sequence (Accession Number MF678788). 170 
Contaminants such as human skin keratin and trypsin were assigned by parallel searching 171 
against the cRAP UniProt database (116 sequences, 38,459 residues; downloaded 30 Jan 172 
2015) database. A concatenated target-decoy database search strategy was also employed to 173 
estimate the rate of false discovery rate. MS/MS search parameters were Search Enzyme: 174 
Trypsin; Max missed cleavages: 1; Fixed modifications: Carbamidomethyl (C); Variable 175 
modifications: Oxidation (M); Mass values: Monoisotopic; Protein mass: Unrestricted; Peptide 176 
mass tolerance: ± 1.2 Da; Fragment mass tolerance:± 0.6 Da;  Instrument type:ESI-TRAP. 177 
MLST designation of strains used.  To establish the MLST (multi locus sequence type) profile 178 
of each of the strains used, Genomic DNA was extracted using the Wizard Genomic DNA 179 
extraction kit (Promega), followed by PCR using the primers previously described (25)   The 180 
purified PCR fragments were sequenced in both directions by GATC Biotech AG using the 181 
same primers. Sequence type (ST) and cluster allelic profiling were determined using the 182 
eBURST V3 software accessible via the Internet-accessible data-base 183 
(http://efaecalis.mlst.net/;) (26, 27). MLST designations are presented in table 3  184 
Phage DNA extraction. To remove contaminating DNA and RNA from the PEG 8000 185 
concentrated phage stocks, a 10 µg/ml DNase and RNAse solution was added and incubated at 186 
37°C for 30 min before 100 µg/ml of proteinase K was added to degrade nucleases at 50°C for 187 
45 min. Removal of proteins from nucleic acids was achieved by extraction with phenol: 188 
chloroform: isoamyl alcohol (25:24:1 v/v). DNA was precipitated by adding two volumes of ice 189 
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cold ethanol and incubated overnight at -20°C before DNA was pelleted at 16,000 xg for 20 min, 190 
and washed with 70%, before DNA was dissolved in sterile milli-Q-water and stored at -20°C. 191 
These samples were used for nucleotide sequencing and restriction fragment length polymor 192 
sm (RFLP) analysis of phage genomes.  193 
Restriction fragment length polymor sm (RFLP) and analysis of phage genome size. 194 
Phage genomic DNA was subjected to restriction digestion with HindIII, Ndel and MfeI, (New 195 
England, Biolabs, UK) according to manufacturers instruction. The digested products were 196 
separated by 1% ETBr-agarose gel electrophoresis to determine RFLP patterns and gels 197 
visualised using an Ingenius 3 gel-doc system, (SYNGENE).  198 
Genome sequencing of phages  SHEF2,  SHEF4 and  SHEF5. Pure phage genomic DNA (20 199 
µg) was sequenced by MicrobesNG on an Illumina MiSeq platform with 2 x 250 bp paired-end 200 
reads before identification of the closest available reference genome using Kraken (28), and 201 
reads mapped using BWA mem (29) to assess the quality of the data. Reads were trimmed 202 
using Trimmomatic (30) before de novo assembly using SPAdes (31). An automated annotation 203 
was performed using Prokka (32), before Mauve align software tool (33) was used to perform 204 
visual multiple comparisons while multiple sequence alignment of individual genes was 205 
performed using Multalin (34). In addition, PHAST (PHAge Search Tool) (35) and PHASTER 206 
(PHAge Search Tool Enhanced Release) (36) web servers were used for further confirmation of 207 
annotated phage genomes. Conserved protein domains (where relevant) were detected using 208 
Pfam (37). Complete genomes were visualized using Artemis (38) and submitted to the NCBI as 209 
individual contigs with accession number MF678788, MF678789 , and MF67878890 for SHEF2, 210 
SHEF4, and SHEF5 respectively.  211 
Biofilm assay on polystyrene plates. The ability of the enterococcal strains to form a biofilm 212 
on an abiotic surface was quantified based on a previously described method (39). Briefly, E. 213 
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faecalis strains were grown overnight in BHI at 37°C. The cultures were diluted 1:40 in fresh BHI 214 
medium and 1 ml of this cell suspension was used to inoculate sterile flat-bottomed 48-well 215 
polystyrene microtiter plates (Cellstar, Greiner Bio-One). Six wells per strain were inoculated 216 
with BHI alone as negative controls. These were then incubated under stationary conditions 217 
(aerobic) at 37°C for the time indicated. For longer term biofilms, the media was changed every 218 
24 h. Broth was then carefully drawn off from wells and 1 ml fresh broth containing 108 PFU/ml 219 
SHEF2 phage or BHI only controls were added before incubation for another 3 h. Wells were 220 
then gently washed three times with 1 ml of phosphate-buffered saline (PBS). The plates were 221 
inverted on a paper towel, air-dried and stained with 1% crystal violet for 15 min. The wells were 222 
washed again 3 times, and the crystal violet was solubilized in 500 µl of ethanol-acetone (80:20, 223 
v/v) and OD570 measured using a microplate reader (Tecan infinite 200, Austria). Each assay 224 
was performed in triplicate and repeated three times. 225 
Adsorption rate experiments. The adsorption rate experiments were performed according to 226 
the procedure described previously (40) with small modifications. Briefly, overnight cultures of 227 
the bacterial strains were diluted 1:100 in BHI medium. When the OD600 of the reference strains 228 
reached 2.0, 1 ml of culture was diluted 10-fold in fresh BHI (5 x 108 CFU/ml). Phages were 229 
added at an MOI of 1 to the diluted culture, mixed gently, and incubated at 37°C. Incubation was 230 
continued for 12 min, with samples (100 µl) collected at one-min intervals and diluted 231 
immediately in 900 µl cooled SM buffer. The diluted samples were centrifuged at 10000 xg 232 
(4°C) for 5 min and passed through a 0.45 µm filter. Finally, the titres of unabsorbed phages in 233 
the supernatant were determined after serial dilution. The adsorption levels were represented by 234 
the percentage of the total number of phages: calculated as follows: [(initial phage titer / free 235 
phage titer in supernatant) /initial phage titer] x 100.  236 
In vitro biofilm assay on tooth root surface. The ability of SHEF2 phage to eradicate E. 237 
faecalis biofilm on extracted natural root surface was quantified based on a previously described 238 
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method using Resazurin dye change (41, 42). To produce a growth surface, 1 mm thickness 239 
root slices were cross sectioned above the root bifurcation area of multi-rooted human teeth 240 
(ethical approval number STH18841) by water cooled 0.1 mm cutting saw (MEDREK 859088) 241 
and were divided into two groups in 24-well microtitre plates (Cellstar, Greiner Bio-One) with 242 
final equal surface area for each group. 7 day (168 h) E. faecalis biofilm was grown as 243 
described previously - i.e. 24 h media changes. After that, the first group (treated) was treated 244 
with 1 ml BHI contain 108 PFU/ml  SHEF2 phage with BHI only used as a control (untreated) 245 
before incubation for another 3 h. The root slices were transferred into 48-well microtitre plates 246 
and washed three times with 1 ml PBS. After treatment and washing, 0.350 ml of PBS 247 
containing resazurin solution at a final concentration of 1 µg/ml were added to both groups in a 248 
48-well plate and incubated at 37°C for 20 min. 0.3 ml from each well of both groups (treated 249 
and untreated) was transferred to 96-well microtitre plates and fluorescence was read using a 250 
microplate spectrofluorometer (Tecan infinite 200 at そexc  570 nm, そem  590 nm). The reading of 251 
the non-emitting dye of resazurin (treated) was subtracted from a control group that contained 252 
only the resazurin dye. This assay was repeated 2 times with at least 3 samples in each group. 253 
In addition we performed a standard curve of bacteria (CFU/ml) vs resazurin (Fig S3C). 254 
Zebrafish as in vivo model for phage treatment. Zebrafish maintenance and experimental 255 
work was performed in accordance with UK Home Office regulations and UK Animals (Scientific 256 
Procedures) Act 1986. Ethical approval was given by the University of Sheffield Local Ethical 257 
Review Panel. Wild-type (WT) inbred zebrafish larvae were obtained from The Bateson Centre, 258 
University of Sheffield. All larvae were maintained in E3 medium at 30°C according to standard 259 
protocols and monitored for up to 4 days post-fertilization (dpf). Groups of at least 20 larvae 260 
were used for each treatment condition. Tricaine-anesthetized embryos were injected 261 
individually with 2 nl of E. faecalis (30,000 CFU) into the Duct of Cuvier of dechorionated 262 
embryos at 30 hours post-fertilization (hpf) and larvae were incubated for 2 h before injection 263 
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with 2 nl of  SHEF2 phage (MOI of 20, in relation to the original bacterial innoculum) or PBS.  264 
Fish health status was monitored for up to 72 hours post-infection (hpi). In parallel larvae were 265 
also injected with either PBS only, E. faecalis only or Phage only alongside heat-killed phage. In 266 
all cases, fish health status was monitored for up to 72 hpi. Zebrafish mortality was assessed 267 
based on the examination of the presence of a heart beat and blood circulation (43). Images of 268 
10% formalin-fixed zebrafish larvae were captured using a fluorescence zoom microscope (Axio 269 
Zoom.V16, Zeiss) with Zen Black software. 270 
Assessment of phage adhesion. Phage adsorption rates were established as described 271 
earlier, with free phage particles of  SHEF2 were counted at 0, 10 minutes, and 24 h post-272 
infection with epaB mutants cells and compared to control OG1RF cells. The free phage 273 
particles was also counted from 24 h suspension after treatment with 1% (v/v) chloroform in 274 
order to lyse all cells to release any possible trapped intracellular phage. In addition, 1 ml 275 
samples from the 24 h phage-bacterial suspension was pelleted and re-suspended in ice cold 1 276 
ml PBS in 0.28 M NaCl (previously shown to breakdown electrostatic interactions between 277 
phage and cell wall material (23) for 10 min at 4°C. These samples were then passed though a 278 
0.45 µm filter to collect phage released, and the titre of free phage in the supernatant 279 
established. The phage count from the 0.28 M NaCl sample was deducted from the free phage 280 
count of the control group of PBS (0.150 M NaCl) to assess how many were adsorbed and 281 
released by increased NaCl. Additionally, and to exclude cell lysis caused by increasing the 282 
molarity of NaCl, CFUs were assessed and compared to the control group. This experiment was 283 
repeated twice in triplicate each time.  284 
Statistical analysis. Statistical analysis was performed using t-test using Graphpad Prism v7.0 285 
(GraphPad, La Jolla, CA) and statistical significance was assumed if p<0,05.  For zebrafish 286 
experiments, Kaplan-Meier survival curves were compared using log rank test and differences 287 
between unhealthy groups were evaluated using One-way ANOVA.  288 
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Isolation and characterisation of bacteriophages targeting E. faecalis  290 
Sheffield wastewater was used as a potential source for E. faecalis specific 291 
bacteriophage (several samples from independent sites). Phage plaques were first identified by 292 
spotting the processed sewage solution on top-agar lawns of a range of orally isolated clinical 293 
strains of E. faecalis (Table 1), with  plaques successfully obtained with E. faecalis OS16, EF2, 294 
EF3 and OMGS3919. To isolate individual phages, this procedure was repeated twice and five 295 
bacteriophages named SHEF2, 4, 5, 6, 7 were identified using a range of E. faecalis isolates 296 
(Figure 1)  297 
Three distinct plaque morphologies were identified with SHEF2, 5, 6 and 7 phage 298 
forming plaques with 3-4 mm diameter surrounded by a thin area of secondary lysis of 1 mm, 299 
while SHEF4 formed 2 mm diameter central plaques surrounded by halos of larger secondary 300 
lysis (Figure 1A).  When infecting the strain OG1RF, SHEF7 formed small pin hole-sized plaque 301 
of 1 mm diameter without distinct secondary lysis while it forms large plaques with OMGS3919 302 
(Figure 1A).   303 
Negative staining transmission electron microscopy of purified phages revealed that all 304 
bacteriophages had polyhedral head-shapes and non-contractile long tails ranging from 200 to 305 
250 nm and polyhedral heads (Figure 1B) with diameters between 41-46 nm (Table 2). 306 
According to the guidelines of the International Committee on Taxonomy of Viruses (ICTV, 307 
2005), the SHEF bacteriophages were classified as belonging to the family Siphoviridae (order 308 
Caudovirales) based upon their tail morphology (44).   309 
Molecular characterisation of isolated phages  310 
 on O














































Digestion of phage DNA with restriction enzymes and DNase I indicated that all isolated 311 
phages were double stranded DNA viruses. Restriction fragment length polymorphism (RFLP) 312 
tests were performed on phage chromosomal DNAs (Figure 1C). The restriction profiles of  313 
SHEF2 and 6 were very similar, whilst all the others were different. From the RFLP analyses, 314 
the five phage genome sizes were estimated to be in the range of 39-43 kbp. Next, we analysed 315 
purified phage particles by SDS-PAGE (Figure 1D).  Distinct protein profiles suggested five 316 
separate phage were isolated.  All samples revealed a prominent band at 36 kDA (Figure 1D), 317 
which Mass Spectrometry confirmed as the phage major capsid protein for SHEF2 (Figure 2, 318 
SHEF2_07). While it is likely that this band is the head protein in all cases, we do not have MS 319 
data to confirm this. In short, we successfully confirmed the isolation of five separate E. faecalis 320 
bacteriophage of the family Siphoviridae.  321 
Determination of host-range 322 
The host-range of the phages isolated was studied using both spot and SAO methods at 323 
MOI of 0.1 to detect visible plaques. All five SHEF bacteriophages were specific to E. faecalis 324 
as none were capable of producing visible plaques using E. faecium (data not shown). Host-325 
range tests showed that all phage have distinct strain specificity preferences, with SHEF2 326 
displaying the broadest host-range with capacity to lyse 9 out of 13 E. faecalis indicator strains 327 
tested, followed by SHEF6 and 7. SHEF5 and 4 possess the narrowest host-range, lysing only 3 328 
and 2 strains, respectively. Despite the similarities between SHEF2 and 6 at the genomic level, 329 
their host-range is not identical, indicating they are distinct phage.   No relationship between 330 
host-range and MLST type was found. 331 
Genome organization of  SHEF2, 4 and 5. 332 
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The genomes of phages SHEF2, 4 and 5 revealed similar sizes of 41.7, 41.1, and 41.6 333 
kbp respectively and appeared to be organised into two halves, transcribed in opposite 334 
directions (Figure 2A). Each genome was assembled into one large contig with low read 335 
mapping coverage at the 5' and 3' ends and no clear edges at the ends of the contigs, 336 
suggesting circularity of terminally redundant permuted genomes. Four gene clusters 337 
corresponding to DNA packaging, structural components, cell lysis and, regulation and 338 
replication were identified (Figure 2A,B). There is little noncoding DNA between these genes, 339 
suggesting single transcripts for each set of genes. Although each phage exhibits a different 340 
host range, a high identity was found for both DNA and primary amino acid level of between 77 341 
and 94% (see Figure S1). Importantly, no putative integrase encoding genes were detected in 342 
the genome sequences, suggesting that the SHEF phages are likely to be lytic in nature. 343 
All SHEF phages share a similar distribution pattern for DNA packaging and head 344 
morphogenesis genes (Figure 2A, orange), and are upstream of the terminase (45, 46). The 345 
predicted head module (Figure 2A, cyan) harbours genes encoding portal proteins (for genome 346 
injection into host cells), prohead protease maturation, head capsid proteins and head-tail 347 
adaptor proteins. These genes are followed by tail and tape-measure proteins (Figure 4A, 348 
green) and a lysis module (Figure 2A, yellow) containing a putative haemolysin XhlA, putative 349 
holin and endolysin genes. SHEF2 and 5 encode putative endolysins (SHEF2_21 350 
andSHEF5_49) with an N-terminal Amidase_2 domain and a predicted C-terminal 351 
ZoocinA_TRD (pfam16775) domain.  SHEF4 encodes a putative endolysin with the same N-352 
terminal domain but an SH3b peptidoglycan-binding domain, indicating differing cell-wall 353 
targeting mechanisms. 354 
The replication and regulation module are also clustered and ordered identically, except 355 
that SHEF4 encodes for an adenine-specific methyltransferase (modification methylase DpnIIB) 356 
that is absent from SHEF5. In addition, SHEF4 and 5 harboured an additional putative 357 
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transcriptional regulator gene that is absent from SHEF2 and suggest that all three employ 358 
slightly different modes of post-replication and DNA modification that might be key during the 359 
infection cycle.  360 
Phage tail proteins are involved in the primary recognition and adsorption to specific 361 
receptors on the bacterial cell surface (47, 48). Since SHEF2, 4 and 5 exhibit different host 362 
ranges, we examined the amino acid sequence of the predicted tail proteins (Figure 2B). The 363 
first three proteins displayed a high sequence similarity (81-100%). In contrast, the N-terminal 364 
130 aa (out of 695 aa) of the fourth tail protein (SHEF2_16, 4_08 and 5_53), shares very high 365 
similarity (>95%) across our phage, while the rest of the sequence was highly divergent (Figure 366 
S2A). We obtained similar results with the fifth tail protein (SHEF2_17, 4_09 and 5_52), where 367 
the first 175 amino acids (out of 800 aa) encode conserved putative tail domains (TIGR01665 368 
and pfam06605), before the rest of the protein sequence diverges (Figure S2B). We propose 369 
that these two genes may be key to the host-range determination of these phage during 370 
infection as has been seen for other E. faecalis phage (51) and represent alternate cell-wall 371 
binding proteins and domains. 372 
 373 
Identification of the enterococcal polysaccharide antigen as the SHEF2 receptor  374 
To gain further insight into the mechanisms driving strain specificity in these phage we 375 
sought to identify the receptor for  SHEF2.  We considered a candidate to be the prominent cell 376 
surface rhamnopolysaccharide enterococcal polysaccharide antigen (EPA) (49-51). The genetic 377 
locus encoding the synthesis of EPA is composed of 18 highly conserved genes (epaA-R) 378 
followed by a variable region which is divergent between strains (Figure 3A) (22), and which has 379 
been proposed to encode strain specific decoration of the core polysaccharide synthesised by a 380 
conserved genetic region (22, 52). Disruption of epaB (strain TX5179(epaB)), a key rhamnosyl 381 
transferase involved in EPA backbone synthesis, abolished infectivity of SHEF2 with infectivity 382 
 on O














































restored upon complementation with a plasmid containing the epaBCD operon (Figure 3B). We 383 
then tested infection of strain oatApgdAdltAsigV, characterised by Smith et al (22) that has 384 
altered Peptidoglycan and Teichoic Acid production, showing that it is still sensitive to infection 385 
and that these molecules are not receptors for SHEF2. 386 
As mentioned above, the core EPA is further decorated by variable chemical 387 
modifications that modulate virulence.  We next tested the infectivity of SHEF2 against mutants 388 
in the epa variable region using mutants previously shown to impair EPA decorations and 389 
virulence (22).  Three of the mutants had insertions in genes encoding glycosyl transferases 390 
(OPDV_11720::Tn, OPDV_11715::Tn and OPDV_11714::Tn) and one had an insertion in an 391 
epimerase gene (OPDV_11707::Tn). All variable region mutants showed a markedly reduced 392 
infectivity by SHEF2 which was restored upon in trans complementation. Interestingly, the 393 
OG1RF_11714 mutant was still partially infected by SHEF2, with a slightly opaque plaque 394 
observed, that was restored to a typical clear plaque by complementation (Figure 3B and S4).   395 
Despite this lack of infection of epa mutant strains, it was still possible that binding 396 
occurred but that the phage was unable to complete its full lytic cycle. To explore this possibility 397 
we carried out an adsorption assay. In this assay, phage and bacteria were incubated together 398 
for 24 hours to allow adsorption of phage/ or infection to proceed before the addition of 0.28 M 399 
NaCl, a treatment known to interfere with electrostatic phage-bacterial interactions, but not harm 400 
Enteroccocus cell viability.  For strain TX5179(epaB) total phage numbers did not increase over 401 
24h- again indicating lack of infection and expansion as compared to the OG1RF strain (Figure 402 
3C).  However, the NaCl treatment released 1.4x105 PFU/ml of phage (51.8%, P<0.01 vs 403 
OG1RF, _11720), reflecting weak adsorption of phage that do not enter a lytic life cycle but are 404 
still viable.  Adsorption without population increase was also observed with the 405 
OPDV_11720::Tn2.5 however less phage were recovered after 0.28M NaCl treatment (1.75%, 406 
P<0.01 vs OG1RF, epaB) indicating a stronger interaction with more phage left adsorbed after 407 
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NaCl treatment. To exclude the possibility that phage progeny were trapped inside the host cells 408 
that could not lyse the host membrane and escape, cell suspensions were treated with 409 
chloroform, with no further release of viable phage particles. Finally, to examine qualitatively 410 
that the released phage is bound to the cells, electron microscopy was performed on OG1RF, 411 
TX5179(epaB) and OPDV_11720::Tn2.5 cells cultured with phage. Indeed phage could be 412 
observed on all these strains (Fig. 3D) indicating that cell surface binding is still occurring in 413 
these mutants and that the core and variable EPA are both bound by phage SHEF2. Like others 414 
(51) we observed rounded cell morphology in TX5179(epaB) (Fig. 3D), and also with the 415 
OPDV_11720::Tn2.5 strain.   416 
Infection parameters and strain preference of  SHEF2  417 
We further characterised the host range and infection characteristics of bacteriophage 418 
SHEF2. As shown in Figure S5A strain OS16 (alongside ER3/2s and EF54) was highly sensitive 419 
to SHEF2, as assessed by time course infection experiments, with cultures lysing within the first 420 
60 minutes, compared to strains such as OMGS3197, 3919 or 3198 which lyse in mid (2h)- and 421 
V583 in late (3h)- exponential phase, respectively (Fig. S5).  As a result and since it is an orally 422 
isolated clinical strain, we used strain OS16 to perform a one-step growth experiment to 423 
establish the eclipse period (average time to produce the first mature intracellular phage), latent 424 
period (average time to cell lysis) and burst size (the average number of phage released at cell 425 
lysis), which showed  SHEF2 as a highly efficient E. faecalis targeting phage with an eclipse 426 
period of only 10 min, a latent period of only 30 min (Figure 4A), and a burst size of 9.3 PFU for 427 
this strain. The plateau phase was reached after 75 min, following a 45 min burst period. Next, 428 
we examined adsorption parameters of this phage with the E. faecalis strain OS16, and found 429 
that saturation of adsorption was reached after 10 min (Figure 4B). This adsorption is illustrated 430 
in Figure 4C where a TEM taken of cells at 30 min post infection illustrates attached phage 431 
attached to the cell surface. 432 
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Ability of  SHEF2 to clear E. faecalis biofilms 434 
Given that most bacteria in nature and in clinical infections reside in biofilms (53, 54) we tested 435 
the ability of  SHEF2 to eradicate  E. faecalis biofilms in vitro on inert polystyrene surfaces, 436 
using a range of strains.  As seen in Figure 5A, we tested the phage against 24h preformed 437 
biofilms, using heat-killed phage as a negative control, and showed phage-dependent 438 
clearance- to varying degrees (3-10-fold), of all sensitive strains (EF54, OS16, OG1RF), while 439 
we observed no clearance for strains EF3 and OG1RF-epaB, which were insensitive to phage 440 
infection in plate based and broth based assays.  In addition, we tested clearance of biofilms of 441 
strains EF54 and OS16, as well as a mixed strain biofilm that had been preformed for 6-days 442 
(FigS3 A,B), again showing clearance of biofilm in a phage dependent manner. 443 
We next tested the efficacy of phage  SHEF2 to eradicate biofilms on natural tooth root 444 
surfaces by growing EF54 biofilms for 168 h before adding  SHEF2 (1x108 PFU/ml) for 3 h, and 445 
achieving a significant reduction in bacterial numbers, as indicated by reduction in detectable 446 
metabolic activity (Figure 5B, P<0.0001) (resazurin assay) to approximately 7x103 bacteria in 447 
total estimated using standard curves of Emission ((@590nm) vs CFU/ml Fig. S3C), from an 448 
original input of over 1x106 (N.B. we were unable to do this on more strains due to limitations of 449 
available tooth slices and ethics restrictions).  We also observed, qualitatively, a drastic 450 
decrease in bacterial material via reduction in visible bacterial biomass visualised as the dark 451 
material in this image using stereomicroscopy and light microscopy (Figure 5C). 452 
Phage treatment evaluation in a zebrafish model of infection 453 
Next, we performed systemic infection studies using an established zebrafish model of 454 
infection (55) and the clinical strain OS16. Zebrafish embryos were infected with E. faecalis for 455 
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two hours before injecting with SHEF2 or a heat-killed sample of SHEF2 at a multiplicity of 456 
Infection (MOI) of 20 (with respect to the E. faecalis inoculum), alongside virus only controls.  457 
Fish mortality and health status was then monitored up to 72 hpi.   E. faecalis OS16 caused a 458 
time-dependent lethality that was significantly higher (p<0,0001) than PBS control or phage 459 
alone (Figure 6A, B). Whilst injection with heat-killed (HK) SHEF2 phage post-infection with 460 
strain OS16 did not improve mortality rates of the zebrafish (73% dead, identical to OS16 only), 461 
injection of live SHEF2 resulted in only 16% death (and thus 84% survival) (p<0.0001, vs OS16 462 
only).  Of note, at fish injected with phage only (SHEF2(LIVE)) or inactivated phage (HK-463 
SHEF2) alone were healthy. Morphology and overall health status of the fish was also 464 
monitored, showing that viable phage allowed recovery from OS16 infection while the HK- 465 
SHEF2 did not (Figure 6B). We also infected embryos with strain EF3, which is not sensitive to  466 
SHEF2 infection (Table 2), but still displayed the ability to cause mortality in embryos by 72 hpi 467 
(90%, p<0,0001) compared to  PBS, live or killed phage alone injected fish (Fig.6B,C).   468 
Significantly, neither viable or heat-killed  SHEF2 phage caused an improvement in survival 469 
when injected alongside strain EF3 with 81.13  (± 5.46%)  and 80.13 (± 1.27%) death 470 
respectively.  In all experiments, the embryos infected with E. faecalis-only displayed a lack of 471 
circulation, yolk sac and eye abnormalities, alongside pericardiac oedema and spine curvature 472 
(Fig. 6D, shown for OS16). In contrast, the majority of phage-treated zebrafish remained healthy 473 
throughout the experiment with health status comparable to phage only and PBS-injected 474 
controls (Figure 6B). 475 
 476 
Discussion 477 
In this paper we report the isolation of 5 lytic phage isolated from wastewater using a 478 
range of oral and non-oral E. faecalis strains. Surprisingly, we were unable to isolate phage 479 
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from oral samples against our strains, even though we could visualise phage in concentrated 480 
saliva (not shown) even though metagenomic evidence from others that the oral cavity is rich in 481 
bacteriophage DNA (56). 482 
All the phage described in this study (SHEF2, 4, 5, 6 and 7) belonged to the family 483 
Siphoviridae, a family of phage previously found to target E. faecalis, (16, 19, 57, 58), alongside 484 
members of the Myoviridae (18, 20, 21).  485 
Our isolated phage (SHEF2, 4, 5, 6 and 7) possessed differing host ranges, with  SHEF2 486 
having the broadest. After genome sequencing we found strong similarity between the genome 487 
sequences of SHEF2, 4 and 5 (SHEF2 is 92-94% identical to  SHEF4 and 5 respectively) but 488 
significant divergence in the putative tail gene locus genes (SHEF2_16, _17,  SHEF4_08, _09, 489 
and  SHEF5_53, _52) with evidence of conserved N-terminal domains but different putative 490 
bacterial surface receptor binding domains in the C-terminus of these proteins. Similar 491 
observations have been made in various species including Lactococcus lactis phage (59, 60) 492 
and Streptococcus thermo lus phage DT1 where interchange of the C-terminal domain of 493 
ORF18 with that of another phage (MD4) altered host-range specificity (61). We suggest that tail 494 
module genes four and five encode host-range specificity determining tail proteins that contain 495 
potentially novel E. faecalis surface binding domains. These findings will open the way for 496 
further investigation of phage host specificity and adhesion of Gram-positive bacteria. 497 
To probe the cell surface receptor for the SHEF2 phage we showed that it was unable to 498 
productively infect insertion mutants with altered core EPA (epaB) or EPA decoration genes. All 499 
decoration mutants showed reduction in infectivity except for OPDV_11714::Tn2.14.. The partial 500 
infectivity of OPDV_11714::Tn2.14 is in line with previous observations showing that mutation of 501 
this gene has only a small impact on EPA decoration (22).  For both the epaB and _11720 502 
(decoration) strains the lack of infectivity is despite the phage retaining the ability to adsorb to 503 
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the bacterial cell surface. Interestingly there is a discrepancy between the amount of phage 504 
recovered from the cell surface of TX5179 and OPDV_11720::Tn2.5 with more phage still 505 
bound to the decoration deficient mutant. This data suggests that SHEF2 likely binds to both the 506 
core polysaccharide and decoration residues, and needs both for infection. In a similar manner, 507 
this is also the case for several well-characterised bacteriophage, e.g. E.coli T4 phage (which 508 
requires LPS and OmpC binding) (62) or S. aureus phage 3C  that requires teichoic and 509 
peptidoglycan for irreversible binding (47, 63).  510 
For phages infecting Gram-positive organisms, the injection of viral DNA requires 511 
crossing the peptidoglycan layer and interaction with the cell membrane. This process has been 512 
studied in L. lactis phages that bind to rhamnose moieties of the cell wall before engaging the 513 
plasma membrane of the host (64-66). This process often employs phage encoded 514 
glycosidases, or lysozyme like enzymes (47), with all the sequenced  SHEF phage also 515 
encoding a tail protein with putative lyzosyme domain (SHEF2_15,  SHEF4_07 and  516 
SHEF5_54). Evidence for two-stage adsorption and infection of E. faecalis exists in the case of 517 
E. faecalis and phage VPE25 infection, where a plasma membrane protein (EF0858) seemed to 518 
be required for lytic infection (and hence DNA injection) but not phage adsorption to the cell 519 
surface receptor (67). We therefore postulate here that the EPA and its variant decoration is 520 
required for productive binding of  SHEF2 to the cell surface of E. faecalis with EPA and an 521 
unknown molecule acting as co-receptor for this phage.   Based on the evidence in the literature 522 
(68, 69) that the Epa PS is not detectable on the outer surface of E. faecalis it is tempting to 523 
speculate that  SHEF2 initially binds first to an outer cell surface PS followed by EPA, but we 524 
have no evidence for this. Overall, further tests are required to establish the primary receptor of  525 
SHEF2 interaction, potentially by producing recombinant versions of the tail protein domains 526 
and investigating their sugar binding properties. Such studies will open new insight into possible 527 
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resistance mechanisms for phage infection but also new targets for anti-infectives against E. 528 
faecalis or strain specific diagnostics based on cell wall component binding capability. 529 
The capacity to form biofilms is critical for E. faecalis virulence, providing resistance to 530 
antibiotics and allowing infections to persist. Studies have shown a strong association between 531 
virulence and biofilm formation with 15-80% of clinical isolates being classified as strong biofilm 532 
formers (70-72)  In addition, 75% of enterococcal infections in humans (bloodstream, urinary 533 
tract, and wound infections) are caused by E. faecalis (2). We showed that SHEF2 can 534 
significantly reduce biofilm formation of a range of sensitive E. faecalis strains (3-10-fold) that 535 
were pre-formed (24h) on polystyrene surfaces (mimicking catheters for example) as well as on 536 
a novel in vitro tooth-cross-section biofilm model (i.e. human tooth cross sections).    We believe 537 
this to be a strong indication that phage therapy based on SHEF2 and potentially our other 538 
phage might be useful for eradication of root-canal infections. In support of our data an ex-vivo 539 
root canal model, developed by Khalifa et al., 2015, was also significantly cleared of bacteria by 540 
phage (20). The use of bacteriophages therefore appears to be a promising strategy to reduce 541 
the biofilm bacterial load associated with E. faecalis infections, providing a potential adjunctive 542 
therapy for root canal infection that has failed to respond to conventional treatment. Other oral 543 
infections such as periodontal disease, which is a complex mixed species infection would 544 
require phages targeting other oral pathogenic bacteria. However, based on reports of phage 545 
targetting Aggregatibacter actinomycetemcomitans (73), and Fusobacterium spp. (74, 75), 546 
alongside several Streptococcus (76),, Veilionella (77) and Neisseria spp (78) in the literature 547 
this may be a feasible future approach.  548 
In addition to oral infections, E. faecalis is a well-known cause of septicaemia (79) with 549 
reports showing that oral bacteria can enter the bloodstream and disseminate systemically, 550 
contributing to infections such as endocarditis and rheumatoid arthritis (79, 80). We tested the 551 
therapeutic potential of the phages we isolated in a well-established in vivo zebrafish embryo 552 
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systemic infection model. We showed, for the first time, that systemic phage treatment after 553 
infection with E. faecalis, dramatically decreased the mortality of zebrafish embryos and greatly 554 
improved their health during infection, indicating the potential of this  phage  in treating systemic 555 
E. faecalis infections. It is important to note that neither the phage or bacterial components 556 
released upon lysis displayed toxicity toward the embryo further demonstrating potential for safe 557 
use of phage systemically. The zebrafish infection model also served extremely well as a 558 
system to test the efficacy of phage against systemic bacteria and act as powerful tool for 559 
monitoring the dynamics of infection and phage clearance of infection that can be monitored in 560 
real-time (81).  Given the effectiveness of the phages described in killing planktonic and biofilm 561 
associated E. faecalis, as well as in a systemic infection model their therapeutic use could be 562 
extended to other infection types such as sepsis, wound infections or urinary tract infections. 563 
It is well documented that bacteria can gain resistance to bacteriophages, and indeed 564 
resistance to E. faecalis phage has been previously reported (82). However, we did not isolate 565 
resistant strains during our experiments, but cannot rule out that this could occur and consider 566 
that the use of a cocktail of phage targeting different cellular receptors would be the best mode 567 
to reduce and combat resistance arising.  Of note here is that resistance arising to at least 568 
phage SHEF2 for example, would require alterations in the EPA core or variable moieties, an 569 
alteration that would likely result in reduced virulence (22).  It is worth noting here that many of 570 
the strains that were sensitive to our small panel of phage in this study were resistant to a range 571 
of antibiotics, including vancomycin (e,g, strain V583), and illustrating that phage have the 572 
potential to be used as an adjunct or alternative treatment in infections caused by antibiotic 573 
resistant strains of important human pathogens.  574 
In conclusion, this study highlights isolation of phage targeting E. faecalis strains 575 
targeting a major virulence determinant of this strain (EPA), and establishes their potential use 576 
in treating biofilm infections by testing them in two clinically relevant model infection systems.  . 577 
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Our work thus strenghtens the possibility of developing phage as therapeutics to combat hard-578 
to-treat oral, topical and systemic infections. 579 
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Table 1. Bacterial strains used in the study.  875 
Bacterial strain  Source          Reference 
E. faecalis   
EF1,EF2,EF3 
OS16 
Oral rinse-endodontic patient (83) 
(84) 
ER3/2s Oral orthograde retreatment (85) 
OMGS3197, OMGS3198 Oral endodontic strains (86) 
 
OMGS3885, OMGS3919 Oral mucosal lesions (86) 
EF54 Non oral human isolate (72) 
OG1RF Oral lab strain (87) 
OG1RF epaB TX5179; 
mutant harbouring an 
insertion in epaB (formerly 
orfde4) 
 (68) 
OG1RF epaB TX5179 
+pTX5249  
Complementation plasmid 
build and strain constructed 
by Zeng et al (2004) 
 (88) 
OG1RF OPDV; OG1RF 
derivative with deletions in 
oatA, pgdA, dltA and sigV 
Constructed by Smith et al 
(2019) 
(22)   
OPDV_11720::Tn2.5; A 
transposon mutant 
harbouring a mutation in 
OG1RF_11720 




built and strain constructed by 




harbouring a mutation in 
OG1RF_11715 




build and strain constructed 




harbouring a mutation in 
OG1RF_11714 
Isolated by Smith et al (22)   (22) 
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build and strain constructed 




harbouring a mutation in 
OG1RF_11714 




build and strain constructed 
by Smith et al (2019) 
(22) 
JH2-2 Non oral lab strain (89) 
E. faecium E1162 Clinical blood isolate; CC17 (90) 
   
 876 
 877 
Table 2. Head and tail dimensions of isolated E. faecalis phages. At least three phage 878 








SHEF2 42.34 ± 
1.0 
231 ± 1.3 
SHEF4 45.60 ± 
1.0 
199.4 ± 0.8 
SHEF5 44.32 ±0.9 240.5 ± 1.5 
SHEF6 45.81 ± 
0.4 
250.6 ± 3.0 
SHEF7 41 ± 0.1 230 ± 2.4 
 882 
 883 
Table 3. Phage-host range of  SHEF phages. (+) indicates a zone of clearance in both spot 884 
and SAO screening tests and (-) no evidence of clearance. The final column indicates MLST 885 
designation established by sequencing according to http://efaecalis.mlst.net/ 886 
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Figure Legends    899 
Strain/Phage SHEF2 SHEF4 SHEF5 SHEF6 SHEF7 MLST  
OS16 + - + + + 173  
ER3/2s + - - + + 21  
EF1 - - + - - 34  
EF2 - + - - - 283  
EF3 - + - - - 97  
EF54 + - - + + 381  
OMGS 3197 + - - + - 21  
OMGS 3198 + - - - - 55  
OMGS 3885 + - - + - 72  
OMGS 3919 + - - + + 97  
OG1RF + - - + + 1  
V583 + - + - - 6  
JH2-2 - - + - - 8  
Total  9 2 4 7 5   
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Figure 1A. Isolation of E. faecalis bacteriophage and plaque morphology. Images of 900 
bacterial plaques formed by the isolated phage in top-agar lawns of E. faecalis OS16 (SHEF2), 901 
E. faecalis EF3 (SHEF4), E. faecalis EF2 (SHEF5) and E. faecalis OMGS3919 (SHEF6 and 7).   902 
SHEF7 is also shown with E. faecalis OG1RF to illustrate plaque morphologies. 903 
1B. Transmission electron micrographs of  SHEF phage particles. Phage were negatively 904 
stained with 0.2 % uranyl acetate as described in methods section. Scale bars (100 nm). 905 
1C. Restriction fragment length polymorphism (RFLP) analysis of extracted phage 906 
chromosomal DNA SHEF2, 4, 5, , and 7  phages genomic DNA was digested with HindIII and 907 
analysed by Agarose gel electrophoresis (inverted image shown alongside GeneRuler 1kb 908 
ladder).  909 
1D. Virion protein profiles of SHEF 2, 4, 5, 6, and 7 by SDS-PAGE with InsatntBlue staining. 910 
The dominant protein band identified my MS/MS as the major capsid protein for SHEF2 at 36 911 
KDa is indicated (*). 912 
 913 
Figure 2. Genome organisation of E. faecalis lytic phages SHEF2, SHEF5, and SHEF4 914 
2A. Images produced using SnapGene® Viewer 1.1.3 Software (DUF- conserved domains of 915 
unknown function). Genome annotation corresponds to GenBank Accession numbers: 916 
MF678788, MF678789, and MF678790 for SHEF2, 4 and 5 respectively; with colours 917 
corresponding to predicted function as indicated in key. 918 
2B. Mauve alignment of tail and lysis genes highlighting areas of conservation.  919 
 920 
Figure 3. Molecular determination of SHEF2 phage adhesion using strain OG1RF.  921 
3A. Schematic of the OG1RF epa core (purple) and variable locus (blue).  Generated using 922 
Snapgene (labelling according to Accession number NC_017316.1). 923 
3B. Table showing qualitative results of spot-assay double layer agar infections of strains listed 924 
with SHEF2 (+:infection; -: no infection) (for pictures see Fig S4). 925 
3C. Phage adsorbtion assay for OG1RF and its isogenic mutant strains epaB and OPDV_11720 926 
(all at 108 CFU/ml bacteria) with SHEF2.  Phage (input: 2x106) were added for 24h before phage 927 
were enumerated in cell supernatants before and after treatment with 0.28 M NaCl by titre 928 
assay.  ND-Not Determined (due to all cells being dead). This experiment was repeated twice in 929 
triplicate each time (mean shown), with one example displayed here. 930 
3D. TEMs of infected OG1RF, epaB and _11720 mutants with SHEF2 at 30 mins post-infection-931 
arrows indicate adsorbed phage. 932 
 933 
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Figure 4. One step growth and adsorption rate characterisation of SHEF2.  934 
4A. One-step growth curve of SHEF2 phage with E. faecalis OS16 as host. The two sets of data 935 
represent samples treated with and without chloroform. Eclipse, burst and latent period are 936 
labelled.  937 
4B. Adsorption of SHEF2 phage to E. faecalis OS16 expressed as a % of total phage added.  938 
4C. Transmission electron micrograph of strain OS16 + SHEF2 at 30 min post infection. black 939 
arrows: spent heads and adsorbed phage;  white arrow- un adsorbed phage. 940 
 941 
Figure 5.  Biofilm assay on polystyrene plates and tooth root slices.    942 
5A. Bar charts represent biofilm growth as measured by Crystal violet staining (measured using 943 
A570 of extracted stain, normalised to cell growth in each well, A600). Samples treated with live 944 
phage are labelled: +SHEF2; while those with heat-killed: +SHEF2 (HK); strain names are as 945 
elsewhere. Mean of 6 polystyrene microtitre wells per condition are shown with SD and students 946 
t-test to compare conditions (P<0.0001).  Experiments were conducted on three separate 947 
occasions, one example shown. 948 
5B. upper: photograph of tooth root slices in-situ treated with  SHEF2 (+SHEF2) or strain EF54 949 
only. The difference in colour represents resazurin reduction to resorufin, and is represented 950 
quantitatively below (mean, SD from 3 readings), with Student's t-test was used to compare 951 
between treated and untreated groups (p<0.0001). 952 
5C.  Stereo microscope (ST-left) and light microscope (LM-right, resazurin stained), images 953 
represent the untreated group (upper) while the lower images  SHEF2 –treated.  Biofilm of E. 954 
faecalis colonies scattered on the root canal surface (RC) and dentinal surface (DS) of the ST 955 
and LM images are shown, respectively.  956 
Figure 6. Phage SHEF2 treatment of E. faecalis OS16-infected zebrafish embryos. 957 
Zebrafish were infected systematically with E. faecalis OS16 strain or strain EF3 at a dose of 958 
30,000 CFU at 30 hpf.  After 2 hours embryos were injected with SHEF2 (SHEF2 LIVE) phage 959 
or heat-inactivated (SHEF2(HK)) at an MOI 20 (in 2nl).  Controls were also performed with 960 
phage only (SHEF2 LIVE or SHEF2(HK)) and PBS (2nl). Data are presented as Kaplan-Meier 961 
survival plots (A,C) as well as bar-chart indicating mortality data at 72hpi or all conditons;  Bars 962 
represent means ± SD. Three independent experiments were performed (n=20 zebrafish per 963 
condition per experiment). Statistical comparison between groups was performed using a log-964 
rank test (A,C) or One-way Anova (B).  (6D) Morphology of zebrafish embryos at 72hpi are 965 
shown injected with PBS, E. faecalis OS16 alone,  SHEF2 LIVE alone or E. faecalis OS16 966 
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followed by  SHEF2 LIVE (D). Red arrows indicate symptoms of infection (eye and yolk sac 967 
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